These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9372064)

  • 1. Treatment of sickling disorders.
    Charache S
    Curr Opin Hematol; 1996 Mar; 3(2):139-44. PubMed ID: 9372064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic reactivation of fetal haemoglobin.
    Olivieri NF; Weatherall DJ
    Hum Mol Genet; 1998; 7(10):1655-8. PubMed ID: 9735388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
    Tantawy AA; Adly AA; Ismail EA; Darwish YW; Ali Zedan M
    Blood Cells Mol Dis; 2014 Dec; 53(4):189-93. PubMed ID: 25065856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Features of β-Thalassemia and Sickle Cell Disease.
    McGann PT; Nero AC; Ware RE
    Adv Exp Med Biol; 2017; 1013():1-26. PubMed ID: 29127675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
    Pearson HA
    Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181
    [No Abstract]   [Full Text] [Related]  

  • 6. Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?
    Segel GB; Simon W; Lichtman MA
    Pediatr Blood Cancer; 2011 Jul; 57(1):8-9. PubMed ID: 21480473
    [No Abstract]   [Full Text] [Related]  

  • 7. [Results and current indications of bone marrow allograft in sickle cell disease].
    Bernaudin F
    Pathol Biol (Paris); 1999 Jan; 47(1):59-64. PubMed ID: 10081781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Options for Sickle Cell Disease.
    Meier ER
    Pediatr Clin North Am; 2018 Jun; 65(3):427-443. PubMed ID: 29803275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental therapy.
    Charache S
    Hematol Oncol Clin North Am; 1996 Dec; 10(6):1373-82. PubMed ID: 8956024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myths and facts...about sickle-cell disease.
    Perry V
    Nursing; 2005 Dec; 35(12):27. PubMed ID: 16331199
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of sickle cell disease.
    Steinberg MH
    N Engl J Med; 1999 Apr; 340(13):1021-30. PubMed ID: 10099145
    [No Abstract]   [Full Text] [Related]  

  • 15. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
    Moutouh-de Parseval LA; Verhelle D; Glezer E; Jensen-Pergakes K; Ferguson GD; Corral LG; Morris CL; Muller G; Brady H; Chan K
    J Clin Invest; 2008 Jan; 118(1):248-58. PubMed ID: 18064299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological induction of foetal haemoglobin synthesis in sickle-cell disease.
    Saleh AW; Hillen HF
    Neth J Med; 1997 Nov; 51(5):169-78. PubMed ID: 9455096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
    Kutlar A; Reid ME; Inati A; Taher AT; Abboud MR; El-Beshlawy A; Buchanan GR; Smith H; Ataga KI; Perrine SP; Ghalie RG
    Am J Hematol; 2013 Nov; 88(11):E255-60. PubMed ID: 23828223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
    JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The increasing complexity of sickle cell anemia.
    Warth JA; Rucknagel DL
    Prog Hematol; 1983; 13():25-47. PubMed ID: 6199811
    [No Abstract]   [Full Text] [Related]  

  • 20. Principles and indications of chronic transfusion therapy for children with sickle cell disease.
    Ware R
    Clin Adv Hematol Oncol; 2007 Sep; 5(9):686-8. PubMed ID: 17982409
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.